Information:
Fel:
ID
21957
Beskrivning
Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00416208
Länk
https://clinicaltrials.gov/show/NCT00416208
Nyckelord
Versioner (1)
- 2017-05-09 2017-05-09 -
Uppladdad den
9 maj 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Multiple Myeloma DRKS00002426 NCT00416208
Eligibility Multiple Myeloma NCT00416208
- StudyEvent: Eligibility
Similar models
Eligibility Multiple Myeloma NCT00416208
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Melphalan High dose Single | Melphalan High dose Consecutive | Transplantation of autologous hematopoietic stem cell First line treatment
Item
patients who have had pretreatment with single or tandem high dose melphalan therapy and autologous stem cell transplantation as first line therapy
boolean
C0025241 (UMLS CUI [1,1])
C0444956 (UMLS CUI [1,2])
C0205171 (UMLS CUI [1,3])
C0025241 (UMLS CUI [2,1])
C0444956 (UMLS CUI [2,2])
C1707491 (UMLS CUI [2,3])
C1831743 (UMLS CUI [3,1])
C1708063 (UMLS CUI [3,2])
C0444956 (UMLS CUI [1,2])
C0205171 (UMLS CUI [1,3])
C0025241 (UMLS CUI [2,1])
C0444956 (UMLS CUI [2,2])
C1707491 (UMLS CUI [2,3])
C1831743 (UMLS CUI [3,1])
C1708063 (UMLS CUI [3,2])
Stable Disease Post Stem cell transplant
Item
at least stable disease after stem cell transplantation
boolean
C0677946 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C1504389 (UMLS CUI [1,3])
C0687676 (UMLS CUI [1,2])
C1504389 (UMLS CUI [1,3])
Laboratory Results Hematologic | Laboratory Results Hepatic | Laboratory Results renal
Item
adequate hematological, hepatic and renal lab parameters
boolean
C1254595 (UMLS CUI [1,1])
C0205488 (UMLS CUI [1,2])
C1254595 (UMLS CUI [2,1])
C0205054 (UMLS CUI [2,2])
C1254595 (UMLS CUI [3,1])
C0022646 (UMLS CUI [3,2])
C0205488 (UMLS CUI [1,2])
C1254595 (UMLS CUI [2,1])
C0205054 (UMLS CUI [2,2])
C1254595 (UMLS CUI [3,1])
C0022646 (UMLS CUI [3,2])
Karnofsky Performance Status
Item
karnofsky status of 70 or more
boolean
C0206065 (UMLS CUI [1])
Non-secretory myeloma
Item
non-secretory multiple myeloma
boolean
C0456845 (UMLS CUI [1])
bortezomib
Item
previous treatment with bortezomib
boolean
C1176309 (UMLS CUI [1])
Allogeneic Stem Cell Transplantation
Item
allogenic stem cell transplantation
boolean
C2242529 (UMLS CUI [1])
Malignant Neoplasm | Basal cell carcinoma
Item
other co-existing malignancy beside basaliome
boolean
C0006826 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
C0007117 (UMLS CUI [2])
Peripheral Neuropathy
Item
peripheral neuropathy
boolean
C0031117 (UMLS CUI [1])
Epilepsy
Item
epilepsia
boolean
C0014544 (UMLS CUI [1])
Comorbidity Severe | Kidney Diseases | Liver diseases | Cardiovascular Diseases | Metabolic Diseases | Communicable Diseases
Item
other severe comorbidities (renal, hepatic, cardiovascular, metabolic, infectious etc.)
boolean
C0009488 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0022658 (UMLS CUI [2])
C0023895 (UMLS CUI [3])
C0007222 (UMLS CUI [4])
C0025517 (UMLS CUI [5])
C0009450 (UMLS CUI [6])
C0205082 (UMLS CUI [1,2])
C0022658 (UMLS CUI [2])
C0023895 (UMLS CUI [3])
C0007222 (UMLS CUI [4])
C0025517 (UMLS CUI [5])
C0009450 (UMLS CUI [6])
Allergic Reaction bortezomib | Mannitol allergy
Item
history of allergic reactions to bortezomib or mannitol
boolean
C1527304 (UMLS CUI [1,1])
C1176309 (UMLS CUI [1,2])
C0571922 (UMLS CUI [2])
C1176309 (UMLS CUI [1,2])
C0571922 (UMLS CUI [2])
Life Expectancy
Item
expected life expectancy of less than 3 months
boolean
C0023671 (UMLS CUI [1])